AUG 02, 2018
FDA Improves Important Compounding Resource
The Food and Drug Administration will add important records to its 503B outsourcing facility product report, giving contact information physicians need to stay updated on compounded-drug availability. The agency notified stakeholders this week that its public-facing outsourcing facility web page will now include updated points-of-contact and phone numbers for each facility. The Academy requested these additions to improve physicians’ ability to engage with the facility directly regarding various compounded drugs’ availability.
The Academy has long sought more frequent updates to the list. This is an important resource, since it outlines specific ophthalmic compounded drugs available through different facilities. While the Academy will still seek a better way to obtain real-time information, we believe having contact information for each facility is a step in the right direction.
You can review the list of currently registered outsourcing facilities — including contact information — here.